Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies [Accessibility Statement] Skip NavigationSpinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platformLead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectivelySAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ...

Avidity Biosciences, Inc. (formerly NASDAQ: RNA, temporarily RNAM) is a clinical-stage biopharmaceutical company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) for serious diseases, including rare genetic cardiomyopathies and neuromuscular disorders. On February 23, 2026, Avidity announced it would convene its special stockholder meeting as scheduled and immediately adjourn it without conducting business. The meeting reconvened on February 26, 2026, ...

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCsâ"¢") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special M ...

Shares of Novartis India Limited jumped sharply on Friday after a ChrysCapital-led consortium announced it would acquire the Swiss pharma giant’s entire 70.68 per cent stake in the listed Indian unit, triggering a mandatory open offer for public shareholders. The stock was trading at ₹953.85 on BSE as of midday, up ₹123.40 or 14.86 per cent from Thursday’s close of ₹830.45. The scrip hit the upper price band of ₹996.50 earlier in the session before easing slightly. Turnover stood at ₹80.72 crore on volumes ...

Group 1 - Daiichi Sankyo has appointed John Tsai, MD as the new Global Head of R&D, effective April 1, 2026, succeeding Ken Takeshita, MD [1] - Dr. Tsai brings over 25 years of experience in driving innovation and leadership in the biotech and pharmaceutical sectors, previously serving at Syncona Investment Management and Novartis AG [1] - The company aims to leverage Dr. Tsai's expertise to enhance its R&D pipeline and accelerate the development of new medicines [1] Group 2 - Daiichi Sankyo has established a new research institute in San Diego, marking its third research facility outside Japan, following locations in Boston and Munich [1] - The company emphasizes its commitment to deepening relationships in key scientific hubs to foster innovation in healthcare [1]

David E. I. Pyott David E. I. Pyott, former Chairman and CEO of Allergan, Inc., was appointed to Tarsus Pharmaceuticals' Board of Directors. IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. “David is one of the most accomplished leaders in eye care, with a strong track r ...

Core Insights - Entera Bio Ltd. has appointed Geno J. Germano as Chairman of the Board, effective February 4, 2026, succeeding Gerald Lieberman [1] - The company is advancing two oral PTH peptide programs into clinical testing in 2026, including a Phase 3 study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in hypoparathyroidism [2] Company Developments - Entera's lead clinical asset, EB613, is positioned to transform osteoporosis treatment by providing an oral anabolic therapy, which could broaden its use among patients [3] - The company has established a foundation for its oral peptide pipeline and is transitioning to late-stage clinical testing, with Germano's leadership expected to enhance its development and commercialization efforts [3][4] Leadership Background - Geno J. Germano brings over 30 years of experience in the pharmaceutical and life sciences sectors, having held senior roles at Pfizer, including leading a $14 billion innovative medicines portfolio [4] - Germano's previous board experience includes roles at various biotechnology companies, indicating a strong background in guiding clinical-stage firms [4] Product Pipeline - Entera is focused on developing oral peptide and protein replacement therapies, leveraging its proprietary N-Tab® technology platform [5] - The company's most advanced product, EB613, is being developed as the first oral treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis [5] - Additional programs include an oral PTH(1-34) tablet for hypoparathyroidism and an oral oxyntomodulin for obesity and metabolic syndromes [5]

Core Viewpoint - Cognizant Technology Solutions Corp. achieved a 6.95% dollar revenue growth in 2025, reaching $21.12 billion, marking its best performance since 2021 and a significant recovery from a revenue decline in 2023 [1] Revenue Growth - Cognizant's growth was primarily driven by product and resource sales, contributing over a third of its revenue growth, which is higher than HCL Technologies' 5.1% growth [2] - The company outperformed major Indian IT firms, with Infosys reporting $19.85 billion (3.85% growth), Tata Consultancy Services at $29.86 billion (down 0.72%), and Wipro at $10.42 billion (down 1.41%) [3] Major Contracts - The company signed three contracts exceeding $1 billion in 2025, including a significant $1 billion IT modernization deal with Novartis AG [4] Future Outlook - Cognizant anticipates revenue between $22.14 billion and $22.66 billion for 2026, indicating a growth rate of 4.9-7.4%, with 1.5% expected from acquisitions [7] - The company is considering a share listing in India to enhance valuations, although specific details remain undisclosed [8] Profitability - Profitability improved, with a 140 basis point increase to 16.1%, although net profit slightly decreased by 0.45% to $2.23 billion [10] Employee Growth - The company increased its workforce to 351,600 employees, gaining 14,800 from the previous year, contrasting with TCS's reduction of nearly 20,000 employees [11] Market Reaction - Following the positive results, Cognizant's shares rose by 2.71% to $76.52 in pre-market trading, indicating strong shareholder confidence [12] Execution and Strategy - The growth is attributed to improved execution and deal conversion rather than a sudden demand rebound, with a focus on large client mining and cost discipline [13]

Core Viewpoint - Avidity Biosciences is set to distribute shares of Atrium Therapeutics to its stockholders as part of a merger with Novartis AG and a spin-off of its early-stage precision cardiology programs [1][2] Company Overview - Avidity Biosciences focuses on RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs), aiming to improve treatment for diseases previously unreachable with existing RNA therapies [3] - The company has developed a proprietary AOC platform that successfully targets RNA delivery into muscle, with ongoing clinical programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy [3] - Avidity is also advancing two precision cardiology candidates targeting rare genetic cardiomyopathies and expanding its pipeline through partnerships in cardiology and immunology [3] Transaction Details - The record date for the distribution of SpinCo shares is set for February 12, 2026, with stockholders receiving one share of SpinCo for every ten shares of Avidity held [1] - The completion of the merger and spin-off is contingent upon certain closing conditions, including stockholder approval, which may affect the record date [2]

Core Insights - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders [1] - The firm is currently investigating multiple companies related to their proposed sales, including The Brand House Collective, Avidity Biosciences, NorthWestern Energy Group, and Two Harbors Investment Corp [1][2][3][4] Company Investigations - The Brand House Collective, Inc. (NASDAQ: TBHC) is set to be sold to Bed Bath & Beyond, Inc., with shareholders expected to receive 0.1993 shares of Bed Bath & Beyond for each share of Brand House [1] - Avidity Biosciences, Inc. (NASDAQ: RNA) is proposed to be sold to Novartis AG, with shareholders receiving $72.00 per share in cash [2] - NorthWestern Energy Group, Inc. (NASDAQ: NWE) is being sold to Black Hills Corp, where shareholders will receive 0.98 shares of Black Hills for each share of NorthWestern, resulting in approximately 44% ownership of the combined company for NorthWestern shareholders [3] - Two Harbors Investment Corp. (NYSE: TWO) is proposed to be sold to UWM Holdings Corporation, with shareholders receiving 2.3328 shares of UWM Class A common stock for each share of Two Harbors [4] Shareholder Votes - The shareholder vote for The Brand House Collective is scheduled for March 17, 2026 [2] - The shareholder vote for Avidity Biosciences is scheduled for February 23, 2026 [3] - The shareholder vote for NorthWestern Energy Group is scheduled for April 2, 2026 [4]